Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

First-Line Treatment for Metastatic TNBC: Pembrolizumab + Chemotherapy

September 19th 2022

Comprehensive insight on use of first-line pembrolizumab plus chemotherapy in patients diagnosed with metastatic TNBC based on results from the KEYNOTE-355 trial.

Dr. Bhatt on the Investigation of Trastuzumab Deruxtecan in HER2-Low Breast Cancer

September 16th 2022

Ruchi Bhatt, DO, discusses the investigation of trastuzumab deruxtecan in HER2-low breast cancer.

Dr. Anne on the Practice-Changing Data of DESTINY-Breast04 in HER2-Low Breast Cancer

September 16th 2022

Madhurima Anne, MD, discusses the practice-changing data of the phase 3 DESTINY-Breast04 trial in patients with HER2-low breast cancer.

Patient Profile 3: A Patient with HER2+ Gastric Cancer Treated With T-DXd–who Develops Neutropenia

September 15th 2022

Centering discussion on a patient profile of HER2+ gastric cancer, experts in oncology discuss the occurrence of neutropenia with trastuzumab deruxtecan therapy.

A Brief Review of Ongoing Clinical Trials of ADCs in Breast Cancer

September 15th 2022

Before closing out their discussion on antibody drug conjugate use in breast cancer management, panelists consider ongoing clinical trials in this setting.

Dr. Modi on Trastuzumab Deruxtecan in HER2-low Breast Cancer

September 14th 2022

Shanu Modi, MD, discusses the significance of the FDA approval of the antibody-drug conjugate trastuzumab deruxtecan in patients with HER2-low breast cancer.

Patient Scenario: A 44-Year-Old Woman With Metastatic TNBC

September 13th 2022

Centering discussion on a patient scenario of metastatic TNBC, Aditya Bardia, MD, MPH, highlights the value of first-line chemoimmunotherapy as a treatment option.

A Brief Overview of Treatment Options for Triple-Negative Breast Cancer

September 13th 2022

Expert oncologist Aditya Bardia, MD, MPH, shares his perspective on mainstay treatment options for patients diagnosed with metastatic triple-negative breast cancer.

Breaking Down Treatment Developments in Breast and Genitourinary Cancers From ESMO 2022: Drs O'Shaughnessy and Choueiri

September 12th 2022

OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Ribociclib Plus Endocrine Therapy Provides Survival Benefit in Advanced HR+/HER2- Breast Cancer With Visceral Metastases

September 12th 2022

Ribociclib plus endocrine therapy elicited statistically significant progression-free survival and overall survival benefits vs placebo plus endocrine therapy in patients with hormone receptor–positive/HER2-negative advanced breast cancer with visceral metastases, including those with liver metastases and multiple metastatic sites.

HRQOL Outcomes in TNBC Are Not Negatively Affected by Pembrolizumab

September 12th 2022

An analysis of patient-reported outcomes from the phase 2 KEYNOTE-522 trial demonstrated that pembrolizumab was not associated with effects on health-related quality of life in patients with triple-negative breast cancer.

Destiny-Breast04 Update Showcases QOL Benefit With Trastuzumab Deruxtecan for HR+, HER2-Low Breast Cancer

September 11th 2022

Trastuzumab deruxtecan demonstrated a promising quality-of-life benefit for patients with hormone receptor–positive, HER2-low metastatic breast cancer, according to a report on patient-reported outcomes from the pivotal DESTINY-Breast04 trial.

Amcenestrant Provides Numerically Similar PFS to Endocrine Therapy in Endocrine-Resistant ER+ Advanced Breast Cancer

September 10th 2022

Amcenestrant did not significantly improve progression-free survival over physician’s choice of endocrine monotherapy in patients with endocrine-resistant, estrogen receptor–positive, HER2-negative advanced breast cancer, but it did provide a benefit that was numerically comparable, according to data from the phase 2 AMEERA-3 trial.

Sacituzumab Govitecan-hziy Demonstrates Promising Efficacy in HER2-low/HER2-0 Metastatic Breast Cancer

September 10th 2022

Sacituzumab govitecan improved progression-free survival and overall response rate among patients with HER2-low or HER2 immunohistochemistry zero, hormone receptor–positive metastatic breast cancer.

Lasofoxifene Improves Responses Vs Fulvestrant in ESR1-Mutated, ER+/HER2- Metastatic Breast Cancer

September 10th 2022

Single-agent lasofoxifene did not produce a statistically significant improvement in progression-free survival vs fulvestrant for patients with estrogen receptor–positive, HER2-negative metastatic breast cancer harboring ESR1 mutations.

Abemaciclib Plus Trastuzumab Results in Numerical OS Improvement Vs SOC in HR+, HER2+ Advanced Breast Cancer

September 10th 2022

The addition of abemaciclib to trastuzumab, with or without fulvestrant, provided a numerical overall survival improvement over standard-of-care trastuzumab plus chemotherapy in patients with hormone receptor–positive, HER2-positive advanced breast cancer, according to data from the monarcHER trial.

Advances in Breast and Gastrointestinal Cancers at ESMO 2022: Drs Rugo and Abou-Alfa

September 10th 2022

First-line Dalpiciclib Significantly Improves PFS Outcomes for Patients With HR+/HER2– Advanced Breast Cancer

September 9th 2022

The combination of the CDK4/6 inhibitor dalpiciclib plus letrozole or anastrozole reduced the risk of disease progression by 49% vs chemotherapy alone in patients with treatment-naïve, hormone receptor–positive, HER2-negative advanced breast cancer.

Oleclumab/Durvalumab Plus Chemotherapy Combo Fails to Reach Clinical Benefit End Point in Advanced TNBC

September 9th 2022

Adding oleclumab to durvalumab and chemotherapy did not increase the clinical benefit rate vs durvalumab plus chemotherapy alone as a first-line treatment for patients with advanced triple-negative breast cancer.

Sacituzumab Govitecan Produces Significant Efficacy Benefits in Pretreated HR+/HER2- Metastatic Breast Cancer

September 9th 2022

Sacituzumab govitecan generated statistically significant and clinically meaningful benefits in overall survival and responses vs physician’s choice of treatment in pretreated patients with hormone receptor–positive, HER2-negative metastatic breast cancer who were resistant to endocrine therapy.